Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solgar Gold Specifics Cholesterol Modulators contains fermented red yeast.

This article was originally published in The Tan Sheet

Executive Summary

SOLGAR GOLD SPECIFICS CHOLESTEROL MODULATORS dietary supplement contains, per three tablets, 300 mg xue zhi kang, or fermented red yeast, as one of the product's "innovative natural ingredients that help maintain healthy cholesterol levels by inhibiting cholesterol production in the liver, interfering with cholesterol absorption and providing powerful antioxidant protection," Solgar Vitamin & Herb says. "As part of a healthy diet and exercise regimen, this formula may not only help reduce total cholesterol levels in blood, but also increase the ratio of HDL (good) cholesterol to LDL (bad) cholesterol -- and prevent oxidation of LDL cholesterol in arteries," the firm claims in a consumer product brochure, Solgar adds. "For many, it may be a natural complement to conventional cholesterol reduction treatments."
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087413

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel